Comorbid anxiety disorders are observed in many patients with attention deficit hyperactivity disorder (ADHD): 25-33% compared to 6-10% in pediatric population. Therapeutic effects of Adaptol have been studied, indicated for children and adolescents with ADHD as monotherapy, in dosages of 25-35 mg/kg for 1-3 months. The positive influence of Adaptol on the core symptoms of ADHD was confirmed: reduction of hyperactivity and impulsivity was registered after 1st month, while clinical manifestations of the attention deficit were decreased on the 2nd-3rd months of the treatment. Anxiolytic activity became apparent from the 1st month and continued to increase on the 2nd-3rd months of the treatment. Simultaneously significant reduction of the oppositional-defiant disorder manifestations were observed.